1506-67-8

Upstream product

• 2029-49-4 2,6-dihydroxymethyl-3-hydroxy-4-pyrone 

Downstream Products

• 958457-37-9 6-(hydroxymethyl)-2-methyl-3-(4-{[3(trifluoromethy)phenyl]oxy}phenyl)-pyridin-4(1H)-one 
• 958457-36-8 6-hydroxymethyl-2-methyl-3-(4-{4-[(trifluoromethyl)oxy]phenyl}oxy)-pyridinone 
• 958457-35-7 6-(hydroxymethyl)-2-methyl-3-(4-{[3(trifluoromethy)phenyl]oxy}phenyl)-4H-pyran-4-one 
• 958457-34-6 6-hydroxymethyl-2-methyl-3-(4-{4-[(trifluoromethyl)oxy]phenyl}oxy)-pyran-4(1H)-one 
• 1334392-90-3 C₂₄H₂₂ClF₃N₂O₄ 
• 1334392-87-8 C₂₄H₂₂ClF₃N₂O₃ 
• 1334392-85-6 C₂₂H₂₀ClF₃N₂O₃ 
• 958457-39-1 3-chloro-6-methyl-4-oxo-3-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-1,4-dihydro-2-pyridinecarbaldehyde 

Relevant academic research and scientific papers

Potent antimalarial 4-pyridones with improved physico-chemical properties

Antimalarial 4-pyridones are a novel class of inhibitors of the plasmodial mitochondrial electron transport chain targeting Cytochrome bc1 (complex III). In general, the most potent 4-pyridones are lipophilic molecules with poor solubility in aqueous medi

Novel heterocyclic compounds

4-pyridone derivatives of Formula I and pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical formulations thereof and their use in chemotherapy of certain parasitic infections such as malaria, are provided.

Cephalosporin compounds and antibacterial agents

Novel cephalosporin compounds represented by formula (I): STR1 wherein R1 represents a lower alkyl group which may optionally have a substituent; each of R2 and R3 independently represents a hydrogen atom or hydroxy group; and A represents a hydrogen atom or a residue of nucleophilic compound, and pharmacologically acceptable salts or esters thereof exhibit a potent antibacterial activity against gram positive and gram negative bacteria.